CAS 59989-18-3

Eniluracil

Description:

Eniluracil is a synthetic compound primarily recognized for its role as an antineoplastic agent, particularly in the treatment of cancer. It functions as a potent inhibitor of the enzyme dihydropyrimidine dehydrogenase (DPD), which is crucial in the metabolism of pyrimidine analogs, such as 5-fluorouracil (5-FU). By inhibiting DPD, Eniluracil enhances the efficacy of 5-FU, allowing for increased therapeutic effects against tumors. The substance is characterized by its chemical structure, which includes a pyrimidine ring, contributing to its biological activity. Eniluracil is typically administered in conjunction with other chemotherapeutic agents to improve treatment outcomes. Its pharmacokinetics involve oral bioavailability, and it is subject to extensive research to optimize its use in oncology. Additionally, safety and side effect profiles are important considerations in its clinical application, as with any chemotherapeutic agent. Overall, Eniluracil represents a significant advancement in cancer treatment strategies, particularly for patients requiring enhanced efficacy from standard therapies.

Formula: C₆H₄N₂O₂

InChI: InChI=1S/C6H4N2O2/c1-2-4-3-7-6(10)8-5(4)9/h1,3H,(H2,7,8,9,10)

InChI key: InChIKey=JOZGNYDSEBIJDH-UHFFFAOYSA-N

SMILES: C(#C)C=1C(=O)NC(=O)NC1

Synonyms:

• 2,4(1H,3H)-Pyrimidinedione, 5-ethynyl-
• 5-Ethynyl-2,4(1H,3H)-pyrimidinedione
• 5-Ethynyluracil
• 5-ethynylpyrimidine-2,4(1H,3H)-dione
• 776C85
• Compound 776C
• Gw776C85
• NSC 687296
• Unii-2E2W0W5Xiu
• Eniluracil

5-ethynyl-1,2,3,4-tetrahydropyrimidine-2,4-dione

CAS: 59989-18-3

Formula: C₆H₄N₂O₂

Purity: 96%

Color and Shape: Solid

Molecular weight: 136.1082

Ref: IN-DA00EEMY

Eniluracil

CAS: 59989-18-3

Eniluracil

Purity: ≥98%

Molecular weight: 136.11g/mol

Ref: 54-BUP06868

5-Ethynyluracil

CAS: 59989-18-3

Formula: C₆H₄N₂O₂

Purity: >97.0%(T)(HPLC)

Color and Shape: White to Light yellow to Light orange powder to crystal

Molecular weight: 136.11

Ref: 3B-E1096

Eniluracil

CAS: 59989-18-3

Eniluracil (GW776C85), oral DPD inhibitor, boosts 5-FU bioavailability to 100%, ensures even absorption & predictable toxicity.

Formula: C₆H₄N₂O₂

Purity: 99.91%

Color and Shape: Solid

Molecular weight: 136.11

Ref: TM-T7614

Eniluracil

CAS: 59989-18-3

Formula: C₆H₄N₂O₂

Molecular weight: 136.11

Ref: 4Z-U-0512

Eniluracil

CAS: 59989-18-3

Eniluracil is a prodrug of 5-fluorouracil, which is an anticancer drug. It is not active when taken orally and must be hydrolyzed by esterases in the stomach to produce 5-fluorouracil. The x-ray diffraction data for eniluracil was collected from untreated human serum samples. Eniluracil has been shown to have matrix effects on solid tumours in mice, leading to increased antitumor activity. This compound also inhibits the enzyme dihydropyrimidine dehydrogenase, which leads to decreased levels of diphosphate nucleotides and accumulation of dinucleotide phosphate. Enlargement of the tumor is also inhibited by this drug due to its ability to inhibit DNA replication and transcription.

Formula: C₆H₄N₂O₂

Purity: Min. 95%

Color and Shape: White Powder

Molecular weight: 136.1 g/mol

Ref: 3D-FE13804

5-Ethynylpyrimidine-2,4(1H,3H)-dione

CAS: 59989-18-3

Formula: C₆H₄N₂O₂

Purity: 98%

Color and Shape: Liquid, No data available.

Molecular weight: 136.11

Ref: 10-F239413